Citius Pharmaceuticals Inc. (CTXR) and Its Rivals Contrasting side by side.

As Biotechnology company, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is competing with its peers based on the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Insider & Institutional Ownership

1.6% of Citius Pharmaceuticals Inc.’s shares are owned by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are owned by institutional investors. On other hand Citius Pharmaceuticals Inc. has 42.8% of its shares owned by company insiders vs. an average of 8.45% insiders ownership for its competitors.


Table 1 has Citius Pharmaceuticals Inc. and its competitors’ return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Citius Pharmaceuticals Inc. 1,997,274,673.93% -52.40% -46.20%
Industry Average 812.10% 105.95% 28.39%

Valuation & Earnings

The following data compares Citius Pharmaceuticals Inc. and its competitors’ valuation, top-line revenue and net profit.

Net Income Gross Revenue Price/Earnings Ratio
Citius Pharmaceuticals Inc. 10.26M 1 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Recommendations

Table 3 shows summary of current ratings for Citius Pharmaceuticals Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Citius Pharmaceuticals Inc. 0 0 0 0.00
Industry Average 1.10 1.78 2.38 2.81

The potential upside of the peers is 168.19%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Citius Pharmaceuticals Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Citius Pharmaceuticals Inc. 21.62% 35% 35% 36.36% -49.06% 29.81%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Citius Pharmaceuticals Inc.’s stock price has smaller growth than the average for its competitors.


The Current Ratio and a Quick Ratio of Citius Pharmaceuticals Inc. are 1 and 1. Competitively, Citius Pharmaceuticals Inc.’s rivals have 7.07 and 6.86 for Current and Quick Ratio. Citius Pharmaceuticals Inc.’s peers have better ability to pay short and long-term obligations than Citius Pharmaceuticals Inc.

Risk & Volatility

Citius Pharmaceuticals Inc. is 53.00% less volatile than S&P 500 because the stock has a beta of 0.47. Competitively, Citius Pharmaceuticals Inc.’s rivals are 76.75% more volatile than S&P 500, because of the 1.77 beta.


Citius Pharmaceuticals Inc. does not pay a dividend.


Citius Pharmaceuticals Inc.’s peers beat on 4 of the 4 factors Citius Pharmaceuticals Inc.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.